Identification of Cardiac Glycosides as Novel Inhibitors of eIF4A1-Mediated Translation in Triple-Negative Breast Cancer Cells
Open Access
Abstract
The eukaryotic translation initiation factor 4F complex (eIF4F) is a potential chemotherapeutic target in triple-negative breast cancer (TNBC). This complex regulates cap-dependent translational initiation and consists of three core proteins: eIF4E, eIF4G, and eIF4A1. In this study, we focus on repositioning compounds as novel inhibitors of eIF4A1-mediated translation. In order to accomplish this goal, a modified synthetic reporter assay was established. More specifically, a (CGG)4 motif, which confers eIF4A dependency, was incorporated into the 5’-leader region of a luciferase-tdTomato lentiviral reporter construct. The Prestwick Chemical Library was then screened in multiple TNBC cell lines by measuring the tdTomato fluorescent intensity. We identified several cardiac glycosides as potential inhibitors of eIF4A1-mediated translation. Based on our studies, we find that cardiac glycosides inhibit the expression of eIF4A1. To identify a potential mechanism by which this was occurring, we utilized the Integrative Library of Integrated Network-Based Cellular Signatures (iLINCS). Our pursuits led us to the discovery that cardiac glycosides also decrease levels of c-MYC. Quantitative PCR confirmed that decreases in c-MYC and eIF4A were occurring at the transcriptional level. As such, disruption of the eIF4A1-c-MYC axis may be a viable approach in the treatment of TNBC. The novel combination of rocaglamide A and digoxin exhibited synergistic anti-cancer activity against TNBC cells in vitro. The findings in this study and others are important for formulating potential combination chemotherapies against eIF4A1 in vivo. Thus, drug repositioning may be one classical approach to successfully target eIF4A1 in TNBC patients.Keywords
Funding Information
- National Institutes of Health (R21CA202176 to DR)
- Ohio Cancer Research foundation (2017 to DR)
- University of Toledo (F110796 start-up to DR)
- University of Toledo College of Graduate Studies (University Fellowship to CMH)
This publication has 68 references indexed in Scilit:
- Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cellsProceedings of the National Academy of Sciences, 2012
- Targeting Synthetic Lethal Interactions between Myc and the eIF4F Complex Impedes TumorigenesisCell Reports, 2012
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient dataThe Lancet Oncology, 2011
- TGF-β Promotion of Gli2-Induced Expression of Parathyroid Hormone-Related Protein, an Important Osteolytic Factor in Bone Metastasis, Is Independent of Canonical Hedgehog SignalingCancer Research, 2011
- The Role of Myc-Induced Protein Synthesis in CancerCancer Research, 2009
- Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK InhibitionCancer Research, 2009
- Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trialThe Lancet, 2009
- Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicityJournal of Clinical Investigation, 2007
- Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4ANature Chemical Biology, 2006
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004